Cargando…

Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease

This minireview provides current summaries of beta-blocker use in the management of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowerin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomiyama, Hirofumi, Yamashina, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941231/ https://www.ncbi.nlm.nih.gov/pubmed/24672712 http://dx.doi.org/10.1155/2014/919256

Ejemplares similares

The current status of beta blockers’ use in the management of hypertension
por: Akbar, Shahid, et al.
Publicado: (2014)

Beta‐blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2017)

Arterial Stiffness, Kidney Function, and Chronic Kidney Disease Progression
por: Townsend, Raymond R., et al.
Publicado: (2013)

Calcium channel blocker in patients with chronic kidney disease
por: Ohno, Shoko, et al.
Publicado: (2021)

Cochrane corner: beta-blockers for hypertension
por: Wiysonge, Charles S, et al.
Publicado: (2018)

The Contribution of Inflammation to the Development of Hypertension Mediated by Increased Arterial Stiffness
por: Tomiyama, Hirofumi, et al.
Publicado: (2017)

Current Knowledge of Beta-Blockers in Chronic Hemodialysis Patients
por: Haddiya, Intissar, et al.
Publicado: (2023)

Beta-blockers and the treatment of hypertension: it is time to move on
por: Wiysonge, Charles Shey, et al.
Publicado: (2007)

Beta Blockers and Melanoma
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease
por: Theodorakopoulou, Marieta P, et al.
Publicado: (2021)

Hypertension Management in Patients with Chronic Kidney Disease
por: Hebert, Sean A., et al.
Publicado: (2022)

Effect of Wave Reflection and Arterial Stiffness on the Risk of Development of Hypertension in Japanese Men
por: Tomiyama, Hirofumi, et al.
Publicado: (2018)

Perioperative use of beta-blockers
por: Priebe, Hans-Joachim
Publicado: (2009)

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions
por: Albouaini, Khaled, et al.
Publicado: (2007)

Role of α1‐blockers in the current management of hypertension
por: Li, Hua, et al.
Publicado: (2022)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

Heart Rate and Cardiovascular Disease: An Alternative to Beta Blockers
por: Liang, Michael, et al.
Publicado: (2009)

The Changing Landscape of Hypertension and the Evolving Role of Vasodilatory Beta-Blockers
por: Bakris, George L., et al.
Publicado: (2007)

Beta-blockers: friend or foe in asthma?
por: Arboe, Bente, et al.
Publicado: (2013)

Beta-Blockers and Cancer: Where Are We?
por: Peixoto, Rita, et al.
Publicado: (2020)

Neuropsychiatric Consequences of Lipophilic Beta-Blockers
por: Cojocariu, Sabina Alexandra, et al.
Publicado: (2021)

Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing
por: Vögele, Anna, et al.
Publicado: (2017)

Topical beta‐blockers in dermatologic therapy
por: Filoni, Angela, et al.
Publicado: (2021)

Hypertension in pediatric patients with chronic kidney disease: management challenges
por: Gallibois, Claire M, et al.
Publicado: (2017)

Bidirectional Longitudinal Relationships Between Arterial Stiffness and Hypertension Are Independent of Those Between Arterial Stiffness and Diabetes: A Large‐Scale Prospective Observational Study in Employees of a Japanese Company
por: Nakano, Hiroki, et al.
Publicado: (2022)

Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease
por: Zvizdic, Faris, et al.
Publicado: (2019)

Management of Hypertension in Chronic Kidney Disease
por: Pugh, Dan, et al.
Publicado: (2019)

Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis
por: Madel, Maria-Bernadette, et al.
Publicado: (2021)

Exploring Sex Differences of Beta-Blockers in the Treatment of Hypertension: A Systematic Review and Meta-Analysis
por: Wilmes, Nick, et al.
Publicado: (2023)

Beta‐Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension
por: Sardana, Mayank, et al.
Publicado: (2017)

Beta-blockers in septic shock: What is new?
por: Lescroart, Mickael, et al.
Publicado: (2022)

Beta-blockers in sepsis
por: Singer, Mervyn
Publicado: (2019)

Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score
por: Iwasaki, Yoichi, et al.
Publicado: (2021)

Treatment optimization of beta-blockers in chronic heart failure therapy
por: Niriayo, Yirga Legesse, et al.
Publicado: (2020)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
por: Strauss, Martin H., et al.
Publicado: (2021)

Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era
por: Jung, Hae Hyuk
Publicado: (2021)

Obesity-related hypertension and chronic kidney disease: from evaluation to management
por: Jung, Mi-Hyang, et al.
Publicado: (2023)

Obesity, hypertension, and chronic kidney disease
por: Hall, Michael E, et al.
Publicado: (2014)

Correction to: Management of Hypertension in Chronic Kidney Disease
por: Pugh, Dan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s83ius4jt8d3aa910pdqo7auef